Copper Depletion Plus Chemo Slows Brain Leukemia in Preclinical Models
Removing dietary copper starves leukemia cells of nucleotide building blocks, boosting methotrexate efficacy against hard-to-treat CNS disease.
Summary
Leukemia spreading to the central nervous system is notoriously difficult to treat, and standard therapies can cause serious brain damage. Researchers at Boston Children's Hospital and Harvard used CRISPR screening to discover that leukemia cells in the cerebrospinal fluid depend heavily on copper for survival. When copper was removed — either by deleting the copper transporter gene SLC31A1 or through dietary restriction — leukemia growth slowed in both the bloodstream and the brain. Mechanistically, copper loss crippled mitochondrial complex IV, which in turn blocked nucleotide synthesis and halted cancer cell proliferation. Combining dietary copper depletion with the standard chemotherapy methotrexate further suppressed leukemia in both cell-line and patient-derived tumor models. This identifies copper restriction as a potentially safe, dietary adjunct to existing leukemia treatment.
Detailed Summary
Central nervous system (CNS) leukemia represents one of oncology's most stubborn problems. The cerebrospinal fluid is nutrient-poor, yet leukemia cells — particularly in acute lymphoblastic leukemia (ALL) — manage to colonize this space and evade standard therapies. Treatments aggressive enough to reach the CNS often cause lasting neurotoxicity, especially in children. Finding gentler, biology-driven strategies to improve CNS-directed therapy is therefore a high priority.
To identify metabolic vulnerabilities unique to CNS leukemia, the research team deployed an in vivo CRISPR screen focused on nutritional dependencies. This approach systematically tested which nutrients or transporters leukemic cells rely upon for survival in the nutrient-sparse CSF environment versus the bloodstream.
The screen pointed strongly to copper. When the copper import transporter SLC31A1 was genetically deleted, or when mice were placed on a copper-depleted diet, growth of both systemic and CNS ALL slowed significantly in xenograft models. Mechanistically, the researchers traced this effect to copper's role in mitochondrial complex IV — the terminal enzyme of the electron transport chain. Without adequate copper, complex IV activity fell, disrupting mitochondrial energy metabolism and, critically, impairing nucleotide synthesis, which cancer cells require to replicate their DNA and divide.
The most clinically actionable finding came from combining dietary copper depletion with methotrexate, a cornerstone of ALL therapy. This combination outperformed either intervention alone in both cell-line-derived and patient-derived xenograft models, suggesting copper restriction could meaningfully amplify existing treatment regimens without adding cytotoxic agents.
Caveats are important: all evidence comes from mouse xenograft models, and the summary is based on the abstract alone. Translation to human patients requires clinical trials, and the precise copper-depletion protocol needed for safety and efficacy in people remains to be defined. Nonetheless, the findings open a compelling dietary-intervention angle in pediatric oncology.
Key Findings
- Dietary copper depletion slowed CNS and systemic ALL growth in mouse xenograft models.
- Copper loss impairs mitochondrial complex IV, blocking nucleotide synthesis needed for cancer cell division.
- Combining copper depletion with methotrexate suppressed leukemia more than either treatment alone.
- Genetic deletion of copper transporter SLC31A1 reproduced the anti-leukemic effect of dietary restriction.
- An in vivo CRISPR screen identified copper as a key nutritional dependency of CNS leukemia cells.
Methodology
The team used a targeted in vivo CRISPR screen to map nutritional dependencies of ALL in both systemic and CNS compartments. Copper depletion was tested via genetic deletion of SLC31A1 and through dietary intervention in cell-line-derived and patient-derived xenograft mouse models. Methotrexate combination experiments were conducted in both model types.
Study Limitations
All findings derive from mouse xenograft models, which may not fully recapitulate human CNS leukemia biology. The optimal degree and duration of copper depletion safe for human patients has not been established. This summary is based on the abstract only, as the full paper is not open access; mechanistic details and statistical robustness cannot be fully evaluated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.